Keyphrases
Omadacycline
100%
Community-acquired Bacterial Pneumonia
100%
Pharmacokinetic Evaluation
100%
Dosing Regimen
100%
Community-acquired Pneumonia
28%
Clinical Evidence
28%
Once-daily
28%
Streptococcus Pneumoniae
14%
Expert Opinion
14%
Special Populations
14%
Methicillin-resistant Staphylococcus Aureus
14%
Legionella
14%
Area Cover
14%
Penicillin Resistance
14%
Multidrug-resistant Streptococcus Pneumoniae
14%
Atypical Bacteria
14%
Mycoplasma
14%
Vancomycin-resistant Enterococci
14%
Resistant Strains
14%
Maintenance Dose
14%
Dose Adjustment
14%
Tetracycline
14%
Hepatic Impairment
14%
Healthy Population
14%
Chlamydia
14%
Haemophilus Influenzae
14%
Moraxella Species
14%
Moraxella Catarrhalis
14%
Methicillin Resistance
14%
Mechanism of Action
14%
Enterococcus Spp
14%
Renal Impairment
14%
Streptococcus Pyogenes (S. pyogenes)
14%
Streptococcus Agalactiae
14%
Empirical Coverage
14%
Patient-centered
14%
New Analogs
14%
Pharmacokinetics-pharmacodynamics (PK-PD)
14%
Pharmacology, Toxicology and Pharmaceutical Science
Bacterial Pneumonia
100%
Omadacycline
100%
Pharmacokinetics
100%
Community Acquired Pneumonia
28%
Streptococcus
28%
Infectious Agent
14%
Penicillin Derivative
14%
Meticillin
14%
Legionella
14%
Methicillin-Resistant Staphylococcus Aureus
14%
Vancomycin-Resistant Enterococcus
14%
Chlamydiae
14%
Tetracycline
14%
Moraxella catarrhalis
14%
Streptococcus Agalactiae
14%
Pharmacodynamic Parameter
14%
Streptococcus pyogenes
14%
Haemophilus influenzae
14%
Maintenance Dose
14%
Mycoplasma
14%